3 latest acquisitions in the cannabis industry
A recent report gave a positive forecast for the industry, stating that it will keep growing and even expand threefold by 2022.
SOURCE: International Business Times AU
FDA Approves Aurinia Pharmaceuticals' (Nasdaq: AUPH / TSX: AUP) LUPKYNIS (voclosporin) for Adult Patients with Active Lupus Nephritis




